GlassScriptPhysician profile
Alexandra Arnold
NPI 1093356511
$1,437.98
in general payments reported to CMS, 2019-2025
21 companies · $630 in 2025
The $630 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $179 · 2024: $484 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $271.48 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $212.69 | 2022-2025 | |
| Pfizer INC. | $195.43 | 2023-2025 | |
| Lilly USA, LLC | $184.13 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $114.02 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $63.26 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $47.26 | 2024-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $45.36 | 2023-2025 | Veozah |
| Amgen INC. | $37.15 | 2024 | Prolia, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $35.43 | 2022 | |
| Hologic Sales and Service, LLC | $25.72 | 2024 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.90 | 2025 | Jardiance |
| Tactile Systems Technology INC | $23.86 | 2025 | Flexitouch Plus, Nimbl |
| Phathom Pharmaceuticals, INC. | $23.35 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $23.20 | 2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.90 | 2024 | |
| Glaxosmithkline, LLC. | $22.41 | 2023 | Shingrix, Arexvy |
| Becton, Dickinson and Company | $19.64 | 2025 | Bd Max System, Bd Max Instrument |
| Seqirus USA INC | $18.69 | 2024 | Flucelvax, Fluad |
| Novartis Pharmaceuticals Corporation | $14.11 | 2024 | |
| Inspire Medical Systems, INC. | $13.99 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.